|
Jul 16
|
Crinetics Pharmaceuticals (CRNX) Gets Initiated With a Hold Rating at Goldman Sachs
|
|
Jul 14
|
Crinetics reveals new data from acromegaly therapy programme
|
|
Jul 13
|
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025
|
|
Jun 30
|
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
|
|
Jun 16
|
Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025
|
|
May 23
|
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
|
|
May 22
|
Is There An Opportunity With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) 20% Undervaluation?
|
|
Apr 11
|
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
|
|
Apr 10
|
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 10
|
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Feb 24
|
Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer
|
|
Feb 20
|
Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences
|
|
Feb 10
|
Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Sep 26
|
Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
|
|
Sep 10
|
Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Sep 5
|
Crinetics Pharmaceuticals, Inc. (CRNX): Among the Best Mid-Cap Healthcare Stocks To Buy Now
|
|
Jun 26
|
Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ...
|
|
Jun 18
|
EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
|
|
May 13
|
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2024 Earnings Call Transcript
|
|
May 11
|
Investors in Crinetics Pharmaceuticals (NASDAQ:CRNX) have seen solid returns of 196% over the past three years
|